2026-10-14T04:53:19Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33993130 2026-09-25T05:33:45Z category_696 portal_316 item_type_3 month_year_09_2026

Supplementary file 1_Impact of immune checkpoint inhibitors as neoadjuvant/perioperative therapy for locally advanced resectable gastric/gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis.pdf Zhengyi Chen (4386883) Xin Liu (43569) Hanling Sun (25107736) Nini Cao (9394415) Junlin Zhou (5159339) Zihan Chen (1765921) Yang Song (88132) Jun Yao (9646) Genetic Immunology gastric/gastroesophageal junction adenocarcinoma immune checkpoint inhibitors meta-analysis neoadjuvant perioperative systematic review Background<p>Immune checkpoint inhibitor (ICI)-based neoadjuvant/perioperative strategies are expanding for locally advanced resectable gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, but the evidence base differs substantially across strategies, and improved pathological response has not consistently translated into survival benefit. We aimed to synthesize strategy-specific comparative and prospective single-arm evidence.</p>Methods<p>PubMed, Web of Science, Embase, the Cochrane Library, and major oncology conference proceedings were searched from inception to August 3, 2026. RCTs and prospective single-arm trials evaluating ICI-containing treatment initiated before surgery were included. Five strategies were evaluated: ICI plus chemotherapy (ICI+CT), ICI plus chemotherapy and anti-angiogenic therapy (ICI+CT+A), ICI plus chemoradiotherapy (ICI+CRT), ICI plus chemotherapy and anti-HER2 therapy (ICI+CT+H), and dual-ICI therapy (ICI+ICI). Random-effects comparative meta-analyses were conducted separately by strategy, while single-arm analyses provided descriptive absolute estimates.</p>Results<p>A total of 74 trials, including 16 RCTs and 58 prospective single-arm trials, were included. In randomized comparisons, ICI+CT was associated with improved pCR (RR, 3.01; 95% CI, 2.19-4.15) and MPR (RR, 1.59; 95% CI, 1.36-1.85) and, in perioperative trials, OS (HR, 0.81; 95% CI, 0.70-0.93) and EFS (HR, 0.74; 95% CI, 0.66-0.83) compared with chemotherapy. ICI+CT+A was associated with improved pCR (RR, 3.43; 95% CI, 1.85-6.37) and MPR (RR, 1.40; 95% CI, 1.12-1.76), but survival evidence was limited to one phase II RCT reporting OS. Comparative evidence for ICI+CRT was limited to one small RCT. Evidence for ICI+CT+H and ICI+ICI was derived mainly from small biomarker-selected noncomparative studies.</p>Conclusions<p>Evidence differed substantially across the five strategies. ICI+CT was associated with improved pCR and MPR and, in perioperative RCTs, OS and EFS; it had the largest and most mature randomized evidence base. ICI+CT+A was associated with improved pCR and MPR, whereas comparative evidence for ICI+CRT, ICI+CT+H, and ICI+ICI remained limited. Further comparative trials are required, particularly for safety and long-term survival.</p>Systematic review registration<p>https://www.crd.york.ac.uk/PROSPERO/view/CRD420251271789, identifier CRD420251271789.</p> 2026-09-25T05:33:45Z Dataset Dataset 10.3389/fimmu.2026.1909466.s001 https://figshare.com/articles/dataset/Supplementary_file_1_Impact_of_immune_checkpoint_inhibitors_as_neoadjuvant_perioperative_therapy_for_locally_advanced_resectable_gastric_gastroesophageal_junction_adenocarcinoma_a_systematic_review_and_meta-analysis_pdf/33993130 CC BY 4.0